Reduction in TIMP‐2 serum levels predicts remission of inflammatory bowel diseases

Growing evidence indicates tissue inhibitors of matrix metalloproteinases (TIMPs) as potential players in inflammatory bowel disease (IBD), but, no prospective data are available in IBD remission/relapse.

[1]  S. Vermeire,et al.  Genetic Deletion of Tissue Inhibitor of Metalloproteinase-1/TIMP-1 Alters Inflammation and Attenuates Fibrosis in Dextran Sodium Sulphate-induced Murine Models of Colitis. , 2016, Journal of Crohn's & colitis.

[2]  J. Satsangi,et al.  Biomarkers in Search of Precision Medicine in IBD , 2016, The American Journal of Gastroenterology.

[3]  W. Sandborn,et al.  C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis , 2015, The American Journal of Gastroenterology.

[4]  S. Gill,et al.  The role of TIMPs in regulation of extracellular matrix proteolysis. , 2015, Matrix biology : journal of the International Society for Matrix Biology.

[5]  J. Gilmer,et al.  Matrix Metalloproteinases in Inflammatory Bowel Disease: An Update , 2015, Mediators of inflammation.

[6]  C. Fiocchi.  Inflammatory bowel disease pathogenesis: Where are we? , 2015, Journal of gastroenterology and hepatology.

[7]  S. Ben-Horin,et al.  Tailoring anti-TNF therapy in IBD: drug levels and disease activity , 2014, Nature Reviews Gastroenterology &Hepatology.

[8]  F. Montecucco,et al.  Pathophysiological role of neutrophils in acute myocardial infarction , 2013, Thrombosis and Haemostasis.

[9]  C. Parkos,et al.  The role of neutrophils during intestinal inflammation , 2012, Mucosal Immunology.

[10]  M. Eisenstein,et al.  Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential , 2011, Nature Medicine.

[11]  K. Kolho,et al.  Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease , 2010, Scandinavian journal of gastroenterology.

[12]  K. Kolho,et al.  Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values , 2009, International Journal of Colorectal Disease.

[13]  W. Stetler-Stevenson.  The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2 , 2008, Cancer and Metastasis Reviews.

[14]  Xu-wen Liu,et al.  Identification of CD63 as a tissue inhibitor of metalloproteinase‐1 interacting cell surface protein , 2006, The EMBO journal.

[15]  Xu-wen Liu,et al.  Novel functions of TIMPs in cell signaling , 2006, Cancer and Metastasis Reviews.

[16]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[17]  R. Flisiak,et al.  Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity. , 2003, World journal of gastroenterology.

[18]  J. Willis,et al.  A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. , 2003, Gastroenterology.

[19]  S. Watson,et al.  Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. , 2003, The American journal of pathology.

[20]  A. Torii,et al.  Vascular smooth muscle cells and pericytes express MMP‐1, MMP‐9, TIMP‐1 and type I procollagen in inflammatory bowel disease , 2001, Histopathology.

[21]  S. Rosewicz,et al.  Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease , 2000, Gut.

[22]  J. Belaiche,et al.  Increased production of matrix metalloproteinase‐3 and tissue inhibitor of metalloproteinase‐1 by inflamed mucosa in inflammatory bowel disease , 2000, Clinical and experimental immunology.

[23]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[24]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.